Recent Developments in Celecoxib-mediated COX-2-independent NF-κB Pathway in Tumor Therapy

doi:10.12114/j.issn.1007-9572.2019.00.434

Abstract

Abstract: Evidence-based studies show that long-term use of non-steroidal anti-inflammatory drugs （NSAIDs） can reduce the incidence of gastrointestinal tumors，so the use of NSAIDs has attracted much attention.Celecoxib，a highly selective cyclooxygenase-2 （COX-2） inhibitor in NSAIDs widely used in anti-cancer research，has fewer toxic and side effects and higher safety compared with traditional NSAIDs.Moreover，celecoxib can also be effective in mediating antitumor pathway in some cancer cell lines that do not express COX-2.To this end，this article reviews recent developments in research on celecoxib-mediated COX-2-independent NF-κB pathway in tumor therapy，and further and comprehensively reveal the anti-tumor mechanism of celecoxib by analyzing responses of tumor cells during the experiments.

Key words: Neoplasms, Celecoxib, NF-kappa B, COX-2 independent pathway：Anti-tumor

摘要： 因循证医学（EMB）证明长期服用非甾体类抗炎药（NSAIDs）可以降低消化道肿瘤发病率，故而NSAIDs的使用备受关注。塞来昔布作为NSAIDs中的高选择性环氧合酶2（COX-2）抑制剂，其较传统NSAIDs具有毒副作用少、安全性高等特点，被广泛应用于抗肿瘤领域的研究。然而塞来昔布在一些不表达COX-2的肿瘤细胞株中亦能发挥有效的抗肿瘤作用。为此，本文就塞来昔布介导的COX-2非依赖的核因子κB（NF-κB）抗肿瘤途径的研究进行综述，通过分析塞来昔布在用于肿瘤细胞实验中介导NF-κB途径引起的多种细胞学效应，更深入、全面地揭示塞来昔布抗肿瘤机制。

关键词: 肿瘤；塞来昔布；NF-&kappa, B；COX-2非依赖途径；抗肿瘤

WANG Yupeng,ZHAO Kui. Recent Developments in Celecoxib-mediated COX-2-independent NF-κB Pathway in Tumor Therapy　[J]. Chinese General Practice, 2020, 23(9): 1195-1198. DOI: 10.12114/j.issn.1007-9572.2019.00.434.
汪煜鹏,赵逵. 塞来昔布介导非环氧合酶2依赖的细胞核因子κB抗肿瘤途径的研究进展[J]. 中国全科医学, 2020, 23(9): 1195-1198. DOI: 10.12114/j.issn.1007-9572.2019.00.434.

References

［1］ZAISS A K，ZUBER J，CHU C，et al．Reversible suppression of cyclooxygenase 2（COX-2） expression in vivo by inducible RNA interference［J］．PLoS One，2014，9（7）：e101263.DOI:10.1371/journal.pone.0101263.
［2］HAN Y D，HONG Y K，KANG J G，et al．Relation of the expression of cyclooxygenase-2 in colorectal adenomas and adenocarcinomas to angiogenesis and prognosis［J］．J Korean Soc Coloproctol，2010，26（5）：339-346.DOI:10.3393/jksc.2010.26.5.339.
［3］TERZUOLI E，MEINI S，CUCCHI P，et al．Antagonism of bradykinin B2 receptor prevents inflammatory responses in human endothelial cells by quenching the NF-kB pathway activation［J］．PLoS One，2014，9（1）：e84358.DOI:10.1371/journal.pone.0084358.
［4］GR?SCH S，TEGEDER I，NIEDERBERGER E，et al．COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib［J］．FASEB J，2001，15（14）：2742-2744.DOI:10.1096/fj.01-0299fje.
［5］KANG K B，ZHU C J，YONG S K，et al．Enhanced sensitivity of celecoxib in human glioblastoma cells：Induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy［J］．Mol Cancer，2009，8：66.DOI:10.1186/1476-4598-8-66.
［6］PARK J S，JUN H J，CHO M J，et al．Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells［J］．Clin Cancer Res，2006，12（16）：4989-4999.DOI:10.1158/1078-0432.CCR-05-2259.
［7］SMALE S T.Hierarchies of NF-κB target-gene regulation［J］．Nat Immunol，2011，12（8）：689-694.DOI:10.1038/ni.2070.
［8］DIXIT V，MAK T W.NF-kappaB signaling.Many roads lead to Madrid［J］．Cell，2002，111（5）：615-619.
［9］LIU W Y，YANG Z，SUN Q，et al．MiR-377-3p drives malignancy characteristics via upregulating GSK-3β expression and activating NF-κB pathway in hCRC cells［J］．J Cell Biochem，2018，119（2）：2124-2134.DOI:10.1002/jcb.26374.
［10］SHISHODIA S，KOUL D，AGGARWAL B B.Cyclooxygenase （COX）-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma：correlation with suppression of COX-2 synthesis［J］．J Immunol，2004，173（3）：2011-2022.DOI:10.4049/jimmunol.173.3.2011.
［11］ARICO S，PATTINGRE S，BAUVY C，et al．Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line［J］．J Biol Chem，2002，277（31）：27613-27621.DOI:10.1074/jbc.M201119200.
［12］ZHOU B P，HU M C T，MILLER S A，et al．HER-2/neuBlocks tumor necrosis factor-induced apoptosis via the akt/NF-κB pathway［J］．J Biol Chem，2000，275（11）：8027-8031.DOI:10.1074/jbc.275.11.8027.
［13］BASU G D，PATHANGEY L B，TINDER T L，et al．Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells［J］．Breast Cancer Res，2005，7（4）：R422-435.DOI:10.1186/bcr1019.
［14］GURPINAR E，GRIZZLE W E，PIAZZA G A.COX-independent mechanisms of cancer chemoprevention by anti-inflammatory drugs［J］．Front Oncol，2013，3：181.DOI:10.3389/fonc.2013.00181.
［15］王云峰，李建，葛成华，等．塞来昔布对不表达环氧合酶-2的胃癌细胞生长的影响［J］．世界华人消化杂志，2009，17（35）：3583-3589.
［16］GHARGHABI M，REZAEI F，MIR MOHAMMADREZAEI F，et al．Celecoxib Treatment Alters p53 and MDM2 Expression via COX-2 Crosstalk in A549 Cells［J］．Iran J Pharm Res，2016，15（2）:483-489.
［17］MCLEMORE T L，HUBBARD W C，LITTERST C L，et al．Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients［J］．Cancer Res，1988，48（11）：3140-3147.
［18］MAIER T J，SCHILLING K，SCHMIDT R，et al．Cyclooxygenase-2 （COX-2）-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells［J］．Biochem Pharmacol，2004，67（8）：1469-1478.DOI:10.1016/j.bcp.2003.12.014.
［19］PINLAOR S，HIRAKU Y，MA N，et al．Mechanism of NO-mediated oxidative and nitrative DNA damage in hamsters infected with Opisthorchis viverrini：a model of inflammation-mediated carcinogenesis［J］．Nitric Oxide，2004，11（2）：175-183.DOI:10.1016/j.niox.2004.08.004.
［20］FENG Y，ZU L L，ZHANG L.MicroRNA-26b inhibits the tumor growth of human liver cancer through the PI3K/Akt and NF-κB/MMP-9/VEGF pathways［J］．Oncol Rep，2018，39（5）：2288-2296.DOI:10.3892/or.2018.6289.
［21］BRABLETZ T，JUNG A，REU S，et al．Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment［J］．Proc Natl Acad Sci USA，2001，98（18）：10356-10361.DOI:10.1073/pnas.171610498.
［22］CHEN Z，LIU M，LIU X J，et al．COX-2 regulates E-cadherin expression through the NF-κB/Snail signaling pathway in gastric cancer［J］．Int J Mol Med，2013，32（1）：93-100.DOI:10.3892/ijmm.2013.1376.
［23］LI Q，LIU B C，LV L L，et al．Monocytes induce proximal tubular epithelial-mesenchymal transition through NF-kappa B dependent upregulation of ICAM-1［J］．J Cell Biochem，2011，112（6）：1585-1592.DOI:10.1002/jcb.23074.
［24］邢飞跃，赵克森，姜勇.NF-κB的信号通路与阻断策略［J］．中国病理生理杂志，2003，19（6）：849-855.DOI:10.3321/j.issn:1000-4718.2003.06.039.
［25］徐洪亮，赵磊，卓德祥，等．NF-κB对PPARδ基因的转录调控［J］．中国生物化学与分子生物学报，2008，24（10）：931-937.DOI:10.13865/j.cnki.cjbmb.2008.10.008.
［26］BEYAZ S，MANA M D，ROPER J，et al．High-fat diet enhances stemness and tumorigenicity of intestinal progenitors［J］．Nature，2016，531（7592）：53-58.DOI:10.1038/nature17173.
［27］SHUREIQI I，JIANG W，ZUO X，et al．The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells［J］．Proc Natl Acad Sci USA，2003，100（17）：9968-9973.DOI:10.1073/pnas.1631086100.
［28］PARK B H，VOGELSTEIN B，KINZLER K W.Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells［J］．Proc Natl Acad Sci USA，2001，98（5）：2598-2603.DOI:10.1073/pnas.051630998.
［29］LI Y J，WEI Z M，MENG Y X，et al．Beta-catenin up-regulates the expression of Cyclin D1，c-myc and MMP-7 in human pancreatic cancer：relationships with carcinogenesis and metastasis［J］．World J Gastroenterol，2005，11（14）：2117-2123.DOI:10.3748/wjg.v11.i14.2117.
［30］LI W，JIANG H R，XU X L，et al．Cyclin D1 expression and the inhibitory effect of celecoxib on ovarian tumor growth in vivo［J］．Int J Mol Sci，2010，11（10）：3999-4013.DOI:10.3390/ijms11103999.
［31］BELKA C，JENDROSSEK V，PRUSCHY M，et al．Apoptosis-modulating agents in combination with radiotherapy-current status and outlook［J］．Int J Radiat Oncol Biol Phys，2004，58（2）：542-554.
［32］HUANG S B，SINICROPE F A.Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells［J］．Autophagy，2010，6（2）：256-269.DOI:10.4161/auto.6.2.11124.
［33］LEV-ARI S，KAZANOV D，LIBERMAN E，et al．Down-regulation of PGE2 by physiologic levels of celecoxib is not sufficient to induce apoptosis or inhibit cell proliferation in human colon carcinoma cell lines［J］．Dig Dis Sci，2007，52（4）：1128-1133.DOI:10.1007/s10620-006-9619-x.

[1]	Chinese Rehabilitation Medicine Association Community Rehabilitation Working Committee. Expert Consensus on Perioperative Nutritional Management for Liver Cancer Based on the Enhanced Recovery after Surgery Concept (2025) [J]. Chinese General Practice, 2026, 29(08): 953-964.
[2]	YAO Wenjing, WANG Cuifeng, GAO Jinliang, REN Meiying, JING Xuefen, FU Yuhua. Autophagy Related Proteins Beclin-1 and LC3-ⅡExpression in Lung Cancer Metaststic Pleural Effusion [J]. Chinese General Practice, 2026, 29(05): 623-630.
[3]	ZHOU Rui, JIN Yue, LIU Tingting, CAI Kerun, CUI Yiyuan, LI Sicong, LIU Lixing, FENG Li, the Working Group for the Clinical Practice Guideline for the Secondary Bone Malignancy with Integrated Traditional Chinese and Western Medicine. Guidelines for Diagnosis and Treatment of Secondary Malignant Tumors of Bone Combined with Traditional Chinese and Western Medicine [J]. Chinese General Practice, 2026, 29(04): 423-435.
[4]	ZHANG Hui, LUO Miaomiao, YU Xiaohang, LIN Xin, YE Lina, TANG Xuan, LI Jiaxue, XIE Xinyu, LAI Li, FENG Yan, LIU Yonghui, CHEN Weigang. The Application Value of a Novel Cell Collector for the Esophagus in Screening for Esophageal Lesions [J]. Chinese General Practice, 2025, 28(35): 4487-4493.
[5]	Community Rehabilitation Working Committee of Chinese Rehabilitation Medicine Association. Chinese Expert Consensus on Constipation Screening and Assessment for Community Cancer Patients (2025 Edition) [J]. Chinese General Practice, 2025, 28(34): 4249-4257.
[6]	Community Rehabilitation Working Committee of Chinese Rehabilitation Medicine Association. Chinese Expert Consensus on Community-based Cancer-related Fatigue Management (2025 Edition) [J]. Chinese General Practice, 2025, 28(33): 4117-4124.
[7]	ZHANG Jia, WANG Hairong, ZHAO Jing, SU Yifan. Influencing Factors of Screening Behavior of First-degree Relatives of Lung Cancer Patients Based on Logistic Regression and Decision Tree Model [J]. Chinese General Practice, 2025, 28(31): 3961-3967.
[8]	LI Jingling, LIU Ning, GUO Jun. Methodological Quality and Metrological Characteristics of Palliative Care Quality Assessment Tools for Cancer Patients: a Systematic Evaluation Based on COSMIN [J]. Chinese General Practice, 2025, 28(31): 3981-3988.
[9]	XU Baichuan, WANG Yan, ZHANG Peng, LI Yiting, LIU Feilai, XIE Yang. Research and Analysis of Screening Tools for Chronic Obstructive Pulmonary Disease Comorbidity Lung Cancer [J]. Chinese General Practice, 2025, 28(30): 3847-3852.
[10]	HU Jieman, TAN Feixiang, YUAN Anxin, CHEN Shiyu, TANG Chulei, YIN Yueheng, BA Lei, XU Qin. Analysis of the Trajectory of Postoperative Frailty and Influencing Factors in Patients with Colorectal Cancer [J]. Chinese General Practice, 2025, 28(26): 3276-3282.
[11]	LIU Yinyin, SUI Hongping, LI Tingting, JIANG Tongtong, SHI Tieying, XIA Yunlong. Advances in Risk Prediction Models for Cardiotoxicity Associated with Breast Cancer Treatment [J]. Chinese General Practice, 2025, 28(24): 3072-3078.
[12]	JIANG Xiaoman, XU Xinyi, DING Lingyu, GUO Yinning, MIAO Xueyi, CHEN Li, XU Qin. Clinical Characteristics and Correlation between Preoperative Frailty and Metabolic Syndrome among Older Patients with Gastric Cancer [J]. Chinese General Practice, 2025, 28(17): 2134-2141.
[13]	CAO Qinhan, ZHUO Xiao, XIA Yuhan, CHE Yangxi, CHEN Min. Interpretation of Updated NCCN Clinical Guidelines for Rectal Cancer (2024.V1/V2) [J]. Chinese General Practice, 2025, 28(17): 2070-2074.
[14]	MA Guifen, ZHANG Qian, SUN Jing. Interpretation of the Key Updates in the Latest Version of 2024 NCCN Clinical Practice Guidelines for Gastric Cancer [J]. Chinese General Practice, 2025, 28(14): 1681-1688.
[15]	YUAN Xiaorui, TAN Yanlin, FU Chun. Construction of the Predictive Model for Lymph Node Metastasis in Patients with Epithelial Ovarian Cancer: Based on ¹⁸F-FDG PET/CT Radiomics Technology [J]. Chinese General Practice, 2025, 28(12): 1465-1472.